Conclusions & Recommendations
TEC 22
22.4.3 - Delaying impact surveys
2020
Heading 2
TEC recognizes that coronavirus safety adaptations may be required to complete surveys. Such adaptations would ideally be agreed between partners and the Ministry of Health prior to implementation.
Conclusion/Recommendation:
No action required
COVID
TEC 22
22.4.2 - Delaying impact surveys
2020
Heading 2
The TEC reflected on their principle that the Zithromax® donation is based on demonstrated evidence of need. If it is safe to conduct field activities, scheduled impact surveys should be conducted prior to potential MDA so that the normal data-driven process is not interrupted.
Conclusion/Recommendation:
No action required
COVID, Zithromax® donation criteria
TEC 22
22.4.1 - Delaying impact surveys
2020
Heading 2
ITI supports country programs to make their own determination when they are ready to restart field activities (surveys and/or MDA) in the context of the COVID-19 pandemic. ITI stands ready to provide Zithromax® when MDA is restarted.
Conclusion/Recommendation:
No action required
COVID
TEC 22
22.3.3 - Compensating for delayed/skipped trachoma treatments (mitigation)
2020
Heading 2
The TEC would welcome requests for operational research on mitigating the effects of skipped treatments in hyper-endemic districts by conducting multiple rounds of MDA in a year with enhanced surveillance. Such proposals should fit the country context, receive country ethical and regulatory approval, and be consistent with MOH/partner resource availability (political will, financial and human resources, and community acceptance).
Conclusion/Recommendation:
This recommendation was further considered during the TEC 23 meeting and at a meeting of TEC members and invited experts on May 11th, 2021.
research, persistence, alternative treatment strategies
TEC 22
22.3.2 - Compensating for delayed/skipped trachoma treatments (mitigation)
2020
Heading 2
The results of some past clinical trials demonstrate that multiple rounds of MDA targeting children may be more successful in controlling trachoma in hyper-endemic areas than standard annual treatment (though this was not studied in the context of mitigation).
Conclusion/Recommendation:
No action required
research, persistence, alternative treatment strategies
TEC 22
22.3.1 - Compensating for delayed/skipped trachoma treatments (mitigation)
2020
Heading 2
Current modelling data predicts that for the majority of trachoma-endemic districts, skipping a round of MDA (i.e., up to 24 months between treatment rounds) will not have a significant negative effect on disease elimination. However, in hyper-endemic districts (defined in the models as TF1-9 ≥40% at baseline), the models predict that skipping a round of MDA could add 2-3 years to the elimination timeline. Further, annual MDA has usually not been successful in controlling trachoma in these areas.
Conclusion/Recommendation:
No action required
research, persistence, end game, alternative treatment strategies
TEC 22
22.2.1 - Zithromax® Supply Chain in the time of COVID-19
2020
Heading 2
TEC recommends continued adherence to the “enhanced” greenlight checklist while the pandemic continues. ITI Supply Chain will re-confirm availability of funds with the donor and timing of MDA with the MOH prior to all shipments.
Conclusion/Recommendation:
This has continued to be a standard operating procedure with all Zithromax®️ shipments.
supply chain, COVID, recommendations for ITI management
TEC 22
22.13.1 - Mozambique
2020
Heading 2
Africa - Central/Southern
The TEC expressed concerns for the internally displaced persons from conflict in Cabo Delgado into trachoma-endemic districts of Nampula. TEC requests more details from the national program about the situation; based on this, the population for these districts may need to be adjusted following the guidelines of the Refugee/IDP algorithm.
Mozambique
Conclusion/Recommendation:
Based on information from other health programs, the national trachoma program requested a 10% increase in the number of Zithromax® treatments for three districts in Nampula with MDAs planned for 2021.
insecurity, special populations, Zithromax® donation criteria
TEC 22
22.12.1 - Tanzania
2020
Heading 2
Africa - East
The Ministry of Health of Tanzania submitted a concept note for an operational research project to determine the impact of nomadic populations on persistent disease in specific districts and to develop strategies for more effectively reaching these groups as distinct populations. The TEC Research Subcommittee will review the concept note and provide feedback to the MOH.
Tanzania
Conclusion/Recommendation:
It was determined that funding is not available for the proposed operational research
research, special populations, persistence
TEC 22
22.11.1 - South Sudan
2020
Heading 2
Africa - East
TEC noted that there was no request for 2021 for the Protection of Civilians (POC) camp located in Juba. The national program has indicated that this is because the camp is due for closure. If the camp is not closed, TEC invites the Ministry to submit a mid-year request after conducting a prevalence survey.
South Sudan
Conclusion/Recommendation:
The recommendation has been shared with the country
special populations, evaluation units